Phentermine-Topiramate

Phase 3Small molecule

MMayo Clinic

Phentermine-Topiramate is one of 100 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisRecruiting

Bipolar DisorderRecruiting

Ulcerative ColitisPhase 2

Recruiting

Bipolar DisorderPhase 3

Recruiting

Competition

Competitive Landscape

91 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Phase 3

10 2

Jyseleca

Gilead

Phase 3

6 3

Skyrizi

AbbVie

Phase 3

6 4

Humira

RRanbaxy Laboratories Limited

Phase 3

19 5

Velsipity

Pfizer

Phase 3

10 6

Mesalazine

Ferring

Phase 3

17 7

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 8

Jardiance

Boehringer Ingelheim

Phase 2

2 9

Atorvastatin Calcium

Merck & Co.

Phase 2

1 10

Zasocitinib

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Obesity

NCT04298203

Q2 2028

ApprovedActive, not recruiting

Obesity

NCT06854614

Q1 2029

Post-ApprovalRecruiting

Bipolar Disorder

NCT07213466

Clinical

Trials by Indication[1]

Obesity4 trials

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

Active, not recruiting·UUniversity of Minnesota·Phase 2·NCT04298203·100 enrolled

Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

Completed·MMayo Clinic·Phase 4·NCT04408586·80 enrolled

Individualized Obesity Pharmacotherapy

Completed·MMayo Clinic·Phase 3·NCT03374956·193 enrolled

Show 1 more trial

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Active, not recruiting·TThe Cleveland Clinic·Approved·NCT06854614·150 enrolled

Ulcerative Colitis1 trial

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

Recruiting·UUniversity of California, San Diego·Phase 2·NCT04721873·40 enrolled

Bipolar Disorder1 trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Recruiting·MMayo Clinic·Phase 4·NCT07213466·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Phentermine-Topiramate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phentermine-Topiramate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phentermine-Topiramate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Phentermine-Topiramate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q1 2029

Trials by Indication[1]

Obesity4 trials

Ulcerative Colitis1 trial

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News